Astex Pharmaceuticals

NCT00005875

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

NCT00005872

Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer

NCT00005874

Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas

NCT00005873

Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00005877

Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer

NCT00005876

Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery

NCT00571662

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

NCT00041990

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

NCT00042003

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

NCT00042016

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

NCT00201721

Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia

NCT00144430

Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children

NCT00453193

Alemtuzumab and Pentostatin In T-cell Neoplasms

NCT00541034

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT00496873

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

NCT01145989

A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01294202

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

NCT01357395

A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer

NCT01627054

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

NCT01652144

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

NCT01696032

SGI-110 in Combination With Carboplatin in Ovarian Cancer

NCT01752933

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

NCT02197676

A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response

NCT03075826

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

NCT02901899

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03700450

Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma

NCT03603964

Guadecitabine Extension Study

NCT03913455

Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

NCT04250246

A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1

NCT04857645

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

NCT05007873

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

NCT05835011

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

NCT06297629

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation